A statement released earlier today by Leerink Partners about Bluebirdbio (NASDAQ:BLUE) bumps the target price to $80.00
- Updated: October 14, 2016
Boasting a price of $65.24, Bluebirdbio (NASDAQ:BLUE) traded -0.47% lower on the day. With the last stock price close up 28.40% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Bluebirdbio has recorded a 50-day average of $63.52 and a two hundred day average of $50.81. Volume of trade was up over the average, with 1,584,592 shares of BLUE changing hands over the typical 1,147,150
Leerink Partners bumped up the target of Bluebirdbio (NASDAQ:BLUE) to $80.00 stating a potential upside of 0.23%.
With a total market value of $0, Bluebirdbio has with a one year low of $35.37 and a one year high of $99.70 .
A total of 14 firms have released a research note on BLUE. Six analysts rating the company a strong buy, six brokers rating the stock a buy, 3 brokerages rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell with a one year target of $89.07.
Brief Synopsis About Bluebirdbio (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.